Dialysis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dialysis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Patiromer to Allow Less Dietary Potassium Restrictions in Patients on Chronic Dialysis with Controlled Blood Potassium Levels https://clinicaltrials.eu/trial/study-of-patiromer-to-allow-less-dietary-potassium-restrictions-in-patients-on-chronic-dialysis-with-controlled-blood-potassium-levels/ Wed, 29 Apr 2026 15:06:54 +0000 https://clinicaltrials.eu/trial/study-of-patiromer-to-allow-less-dietary-potassium-restrictions-in-patients-on-chronic-dialysis-with-controlled-blood-potassium-levels/ This study focuses on patients with End Stage Kidney Disease who are receiving chronic dialysis therapy. The research examines the effects of patiromer, a medication that binds to potassium in the body, compared to placebo. The purpose is to determine if this treatment allows patients to reduce or eliminate their dietary restrictions on potassium-rich foods without increasing the risk of having high potassium levels in their blood.

The medication being tested, Veltassa, comes as a powder that is mixed with liquid and taken by mouth. Patients will receive either Veltassa or placebo for three months while continuing their regular dialysis treatment. During this time, doctors will monitor the amount of potassium in patients’ blood and assess whether they can safely include more potassium-containing foods in their diet.

The study will track several health factors, including changes in blood potassium levels, quality of life, and whether patients need additional treatments to manage their potassium levels. The research will also monitor if patients can better tolerate certain heart and blood pressure medications that are typically challenging to use in dialysis patients due to their effects on potassium levels.

]]> Study on Low Dose Rivaroxaban for Heart and Blood Vessel Disease in Patients with Advanced Kidney Disease or on Dialysis https://clinicaltrials.eu/trial/study-on-low-dose-rivaroxaban-for-heart-and-blood-vessel-disease-in-patients-with-advanced-kidney-disease-or-on-dialysis/ Wed, 29 Apr 2026 14:28:15 +0000 https://clinicaltrials.eu/trial/study-on-low-dose-rivaroxaban-for-heart-and-blood-vessel-disease-in-patients-with-advanced-kidney-disease-or-on-dialysis/ This clinical trial is focused on studying the effects of a medication called Rivaroxaban on people with advanced chronic kidney disease (CKD) who also have heart and blood vessel disease, known as cardiovascular disease. The study aims to see if taking a low dose of Rivaroxaban, which is a type of blood thinner, can help reduce the risk of serious heart-related events such as heart attacks, strokes, or problems with blood flow in the legs. Participants in the study will either receive Rivaroxaban or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to determine if Rivaroxaban can significantly lower the chances of cardiovascular death or other major heart-related issues in people with advanced CKD, including those who are on dialysis. Dialysis is a treatment that helps clean the blood when the kidneys are not working well. The study will involve taking the medication twice daily over a period of time, and participants will be monitored for any changes in their health related to heart and blood vessel conditions.

Throughout the study, researchers will keep track of various health outcomes to understand the potential benefits and risks of using Rivaroxaban in this group of patients. The study is expected to provide valuable information on whether this medication can be a safe and effective option for people with both advanced kidney disease and cardiovascular disease.

]]>